- Science
- Clinical Trials
- Guide to Clinical Trials Your participation makes a difference
- Clinical Trials in Children Designed to improve kids' health
- Data and Results Sharing our Results
- Integrity and Transparency Building Trust
- Diversity Equity and Representation
- Plain Language Study Results Trial Result Summaries
- Expanded Access & Compassionate Use Possible Treatment Options
- Find a Trial
- Areas of Focus
- Rare Disease Smaller populations but big impact
- Internal Medicine Extending lifespans worldwide
- Inflammation & Immunology Treatment at the molecular level
- Vaccines Preventing the spread of infections
- Oncology The science of optimism
- Anti Infectives Combatting an evolving risk
- Areas of Innovation
- Gene Therapy Breakthroughs become treatments
- Medicinal Sciences The next generation of science
- Precision Medicine Developing tailored medicines
- Maternal Immunization Protecting newborns at the start
- mRNA Technology Unleashing the next wave of scientific innovations
- Diseases & Conditions
- Coronavirus Resources
- Product Pipeline
- Research Sites
- Clinical Trials
- Products
- How Drugs are Made
- Branded vs. Generic Learn the difference
- Biologics & Biosimilars Cures found in nature
- Commitment to Quality Maintaining the highest standards
- Global Supply Strategic manufacturing locations
- Manufacturing Sites Where medicine is made in the U.S.
- Medicine Safety
- Health Literacy Learning to be well
- Treatment Choices Learning about treatment decisions
- Partnering With Patients Helping others by reporting side effects
- Tips for Patients Preventing medication errors
- Reporting Adverse Events
- Counterfeiting Preventing medication errors
- Safety Data Sheets
- Product List
- Product Contacts
- PfizerPro for Professionals
- Patient Assistance Programs
- Distributors
- How Drugs are Made
- Stories
- Newsroom
- About
- People
- Executives Our senior-most leadership
- Board Members The people steering our company
- Scientists Our experts making discoveries
- Patient Stories Our patients
- Colleague Stories Our colleagues
- Responsibility
- Ethics & Compliance Each of us is responsible
- Diversity, Equity, and Inclusion Everyone has something to offer
- EHS Governance
- Environmental Sustainability Our responsiblity to the environment
- Global Impact Meeting urgent needs worldwide
- Health & Safety
- Human Rights Furthering dignity and worth
- Intellectual Property The benefits of fair competition
- Patient Advocacy & Engagement Putting Patients First
- Programs & Policies
- Grants Support for independent research
- Political Partnership Supporting like-minded organizations
- Working with Healthcare Professionals Collaboration to improve lives
- Prescription Value & Pricing How to lower patient costs
- Privacy Principles Commitment to personal data privacy
- Ready for Cures Improving Access to Medicines
- Transparency in Grants Committed to Disclosure
- Investors
- Investors Overview Information for stockholders
- Why Invest Why to join us in our mission
- Events & Presentations Calendar of upcoming events
- Financial Reports Quarterly reports and more
- Investor News Announcements about our performance
- Stock Information Charts and data
- Shareholder Services Information on stock transactions
- Corporate Governance
- Corporate Governance Overview Gaining insight into our performance
- Board Committees & Charters Defining the corporate structure
- The Pfizer Board Policies Ensuring ethical leadership
- Corporate Governance FAQs Learn more about our approach
- Contact Our Directors Email any of our Directors
- History
- Careers
- Partners
- People
Time is flying. It has been six weeks since my arrival in Beijing as a Pfizer Global Health Fellow. I am working with US Center of Disease Control and Prevention (CDC) Beijing Office for four months. In this program, I work along with US and China CDC colleagues evaluating the nature of newly emerging infectious diseases, studying how contagious they are and what the diseases transmission paths are. In the end, we want to understand what we can do to prevent further outbreak.
As many of you know from the media that there was a new bird flu virus H7N9 outbreak in China that started in March 2013. So far there are 123 confirmed cases and 23 deaths. An important role of US CDC Beijing office is to provide consultation and technique assistance (as needed) to China CDC to monitor and contain new flu viruses. Pandemics of SARS in 2003 and H1N1 bird flu virus in 2009 taught us all how important the global corporations are to fight and prevent global outbreak of a new infections disease. Those lessons have prepared Chinese government for this new virus outbreak. China CDC, US CDC, and World Health Organization (WHO) are working closely monitoring the situation. Information seems to be more readily available to public this time, and the public is handling the H7N9 virus pretty well. There is no public panic at all this time. The group I am working with is called International Emerging Infections Program (IEIP). This group is proactively looking for new infectious diseases which may become new threat to public health. What they do is working with China CDC to perform observational studies to identify disease burdens (prevalence) and risk factors for targeted diseases. The diseases in study include Pneumonia, Tuberculosis, and food-borne infections from seafood. My main role is to provide consultation in data management, data cleaning, and statistical analyses. There are no statisticians in the office. I feel I am well welcome. Hope my stay could make meaningful contribution to the team. Since I was born and raised in China, there is no language obstacle for me in Beijing. Bilingual in Chinese and English helps me greatly to my work. However culture differences in work place exist, it takes me a while to get use to it. From this fellowship program, beside the CDC assignment, I am also interested in exploring the differences of clinical practice / operation between US and China. By knowing the differences, I hope to gain better understanding of the potential impact to Pfizer’s global clinical trial.
